Building trust together.

# CERTIFICATE

**THE STANDARDS INSTITUTION OF ISRAEL**

*has issued an IQNET recognized certificate that the organization:*

## NANO Z COATING LTD.

1, Shidlovski St., Yavne, Israel

**Has implemented and maintains a Quality Management System**

For the following scope:

**Manufacture and sale of double-active disinfectant whit continuous protection (CPD-continue protection disinfection). Manufacture of antibacterial wipes and HWC wash cloth for human body.**

which fulfils the requirement of the following standard:

**ISO 13485:2016**

| | |
|---|---|
| **Issued on:** | **02/05/2024** |
| **First issued on:** | **28/04/2022** |
| **Expires on:** | **02/05/2027** |

**Registration Number: IL - 118411**

*Alex Stoichitoiu*
*President of IQNET*

*Avital Weinberg*
*Director, Quality & Certification Division*

This attestation is directly linked to the IQNET Members original certificate and shall not be used as a stand-alone document

**IQNET Members***:
**AENOR** *Spain* **AFNOR Certification** *France* **APCER** *Portugal* **CCC** *Cyprus* **CISQ** *Italy* **CQC** *China* **CQM** *China* **CQS** *Czech Republic* **Cro Cert** *Croatia* **DQS Holding GmbH** *Germany* ***EAGLE Certification Group*** *USA* **FCAV** *Brazil* **FONDONORMA** *Venezuela* **ICONTEC** *Colombia* ***ICS*** *Bosnia and Herzegovina* **INTECO** *Costa Rica* **IRAM** *Argentina* **JQA** *Japan* **KFQ** *Korea* **LSQA** *Uruguay* **MIRTEC** *Greece* **MSZT** *Hungary* **Nemko AS** *Norway* **NSAI** *Ireland* ***NYCE*-SIGE** *México* **PCBC** *Poland* **Quality Austria** *Austria* **SII** *Israel* **SIQ** *Slovenia* **SIRIM QAS International** *Malaysia* **SQS** *Switzerland* **SRAC** *Romania* **TEST St** Petersburg *Russia* **TSE** *Turkey* **YUQS** *Serbia*

* The list of IQNET Members is valid at the time of issue of this certificate. Updated information is available under www.iqnet-certification.com

www.sii.org.il

**STUDY REFERENCE: VV_CC-HRIPT/50D1_699_21_001**

**Study Report - Version nº 2**

# ASSESSMENT IN HUMANS OF THE CUTANEOUS COMPATIBILITY AND THE ABSENCE OF ALLERGENIC POTENTIAL OF A COSMETIC PRODUCT AFTER REPEATED UNDER PATCH APPLICATIONS WITH DERMATOLOGICAL CONTROL

## HUMAN REPEATED INSULT PATCH TEST (HRIPT)

**SPONSOR:** NANO Z COATINGS LTD
**TESTED ELEMENT:** *HWC - DRY CLOTH SOAKED IN SOAP*
**REFERENCE:** -

Madrid, October 15th, 2021

*All the changes on the present report respect to the previous version are indicated in italics*

**REPORT INDEX**

## 1. SYNOPSYS

| SPONSOR | NANO Z COATINGS LTD |
|---|---|
| **Tested product** | Product name: *HWC - DRY CLOTH SOAKED IN SOAP*<br>Product reference: -<br>Batch: 2923 |
| **Testing Facility** | ZURKO RESEARCH S.L<br>Avenida de la Osa Mayor, 4. 28023, Madrid (España)<br>Tel: (+34) 91.521.15.88 |
| **Technical team** | Laboratory director: María Barbero Calderón, pharmacist<br>Tolerance Department manager: Jesús González Cuartero, pharmacist<br>Researcher: Jesús González Cuartero, pharmacist<br>Technician: Ainhoa Yepes Agudo, Inés Rodríguez de Roa Peñarando<br>Dermatologist: Javier Pedraz Muñoz. Medical license number: 283706434 |
| **Study code** | VV_CC-HRIPT/50D1_699_21_001 |
| **Panelists** | Number of panelists enrolled: 61<br>Gender: both<br>Age range: 18-70 years<br>Skin type: sensitive skin according to center criteria<br>Number of panelists completed: 52 |
| **Test area** | Upper back |
| **Application** | Duration: 40 days<br>Frequency: repeated applications under patch |
| **Test period** | August 30th, 2021 –October 7th, 2021<br>*Final report version no. 1: October 14th, 2021* |
| **Test parameters** | Cutaneous evaluation of erythema and oedema |
| **Design of study** | Day 1, 3, 5, 8, 10, 12, 15, 17, 19, 36 – Sample preparation and application<br>Day 3, 5, 8, 10, 12, 15, 17, 19, 22, 36, 38, 39, 40 – Clinical and dermatological evaluation |
| **Evaluation** | Cutaneous Mean Irritation Index (M.I.I.) and allergenicity |

**Results:**

Under adopted experimental conditions, the product, ***HWC - DRY CLOTH SOAKED IN SOAP*****,** reference: **-** has **Intermediate Cutaneous Compatibility, 31%** of the panelists showed some kind of erythema or oedema reaction to the product during the induction phase.

Under the experimental conditions adopted, **No allergenicity** has been observed in any of the tested panelists.

## 2. OBJECTIVE AND PRINCIPLE OF THE STUDY

This study had as an objective verifying the cutaneous compatibility and the absence of allergenic potential of a cosmetic product after repeated skin applications, under exaggerated experimental conditions.

The product was applied to the skin under patch 9 times during 3 consecutive weeks. After a minimum of two weeks of rest with the patch application, the product was reapplied under patch in duplicate sites.

The compatibility of the product with the skin was verified, after removing the patch, and through visual examination of the experimental area, by the responsible technical expert and the dermatologist in charge of the study.

The method used is an adaptation of the one described by Marzulli and Maibach (Marzulli F.N., Maibach H.I., Contact allergy: predictive testing in man, Contact dermatitis, 1976, 2, pp.1-17).

The study was carried out following general conditions in Zurko Research, established for the execution of study project on humans (Structure and Content of Clinical Study Reports from ICH Harmonised Tripartite Guideline; Guideline for good clinical practice E6 (R2) of June 14th 2017, EMA/CHMP/ICH/135/1995 of May 1st 1996, European Parliament and Council Guideline 2001/20/CE – May 1st 2001).

The negative control excluded false positives.

## 3. PANELISTS

### 3.1. Ethical aspects

Each participating panelist in the study was previously informed about the type and the procedures of the study and signed an Informed Consent Form before the beginning of the study.

### 3.2. Specific inclusion and exclusion criteria

The specific inclusion criteria, defined in the protocol, were as follow:

- Age: 18-70 years old
- Photo-type (Fitzpatrick): I to IV
- Skin type: sensitive skin according to center criteria

The specific exclusion criteria, defined in the protocol, were as follow:

- Cutaneous marks on the experimental area that could interfere with the evaluation of the skin reactions (pigmentation disruptions, scars, excessive hair areas, excessive freckles and moles, solar skin burns, tattoos…)
- Injuries, pathologies or infection in the experimental area
- Eczematous reaction which has not fully disappeared, scar or pigmentation complications from previous studies in the experimental area

- Have the intention of bathing in bathtub, sea or pool or going to sauna or Turkish bath during the study
- Intense sun exposure or UV rays during the study, or having sunbathed or UV rays during the month prior to the study on the test area
- Carrying out a treatment containing acid vitamin A or its by-products, during the 3 months previous to the study
- Carrying out a treatment containing topical corticoids, on the experimental area during the 8 days previous to the beginning of the study
- Carrying out a treatment with any medicine for psoriasis or vitiligo, during the month previous to the study
- Having the intention to be vaccinated during the study or have been vaccinated during the 3 weeks previous to the study
- Being pregnant or breastfeeding period
- Allergies to metals
- Reactivity to medical tape
- Participation during the previous 30 days in any study under exaggerated conditions (under a patch).

Information about the participating panelist is included in Annex I.

## 4. METHODOLOGY

### 4.1. Criteria for application the product

Type of product: textile fabric.

Product preparation: the sample is cut in pieces of 0,25 $cm^2$.

Applied quantity: a piece of 0,25 $cm^2$ prepared over occlusive patch (Finn Chamber Aqua® occlusive patch).

### 4.2. Chronology of the study

Test duration: 6-8 consecutive weeks (40 days) without considering the re-challenge phase.

**First phase: Induction Phase** lasts three weeks:

- Application of the product under patch on days 1, 3, 5, 8, 10, 12, 15, 17, 19.
- Patch removal by the panelist at home on days 2, 4, 6, 9, 11, 13, 16, 18, 20 (after 24 hours of the application of the patch).
- Skin examination at 24 hours after patch removal on days 3, 5, 10, 12, 17, 19.
- Skin examination at 48 hours after patch removal on days 8, 15, 22.
- If excessive irritation develops anywhere, the product that cause the irritation is not reapplied and the panelist is excluded from the study.

**Second phase: Rest phase**. The duration was minimum 2 consecutive weeks and maximum 4. In this phase the product under study was not applied.

**Third phase: Challenge** or **Memory phase**: 1 week.

- Skin examination and application of the product under patch on Monday. The patch is applied in two areas, the induction area and the virgin area
- Patch removal by the panelist him/herself at home after 24 hours of the application.
- Skin examination 24 and 48 hours after the patch removal. 72 hours after the patch removal the skin is examined in those panelists who were reactive during the memory phase. For those panelists in which no reaction was observed, a negative result is assumed also on 72 hours.

Alternatively, the fourth phase: **Re-challenge phase.** It can be performed between 4 and 12 weeks after the initial challenge phase. Panelists who exhibit in challenge phase an inconclusive response and/or more information about challenge response is needed, a re-challenge can be performed between 4 and 12 weeks after the initial challenge phase. The experimental procedure is the same that challenge phase.

### 4.3. Experimental procedure

| | | Day |
|---|---|---|
| Induction | Informed Consent Form signature | 1 |
| | Specific inclusion and exclusion criteria | 1 |
| | Patch application | 1, 3, 5, 8, 10, 12, 15, 17, 19 |
| | Evaluation after 24 hours of the patch removal by the panelists their selves and before reapply the patch | 3, 5, 8, 10, 12, 15, 17, 19, 22 |
| Two weeks rest | | |
| Challenge | Duplicate patch application | 36 |
| | Evaluation after 24 hours of the patch removal | 38, 39, 40 |

Each day of evaluation the product is assigned an erythema score according the following scale:

| Score | Assessment of reaction | PARAMETERS EVALUATED | |
|---|---|---|---|
| | | Erythema (E) | Oedema (OE) |
| 0 | Absence | No visible erythema | No visible oedema |
| 1 | Slight | Slight erythema (quiet pinked coloration of the complete tested area or rather visible on one part of the tested area) | Slight oedema (palpable and visible) |
| 2 | Moderate | Obvious erythema (clear erythema covering all of the tested area) | Obvious oedema with or without vesicle/s |
| 3 | Severe | Intense erythema (severe erythema covering all the tested area or erythema diffusing outside the tested area) | Intense oedema (extended area outside the tested area) with or without vesicle/s or blister/s |

Table 1. Clinical Examination of Erythema and Oedema Scoring

Other elevated responses could be observed, if present, are graded as independent responses:

- **P** Papules – many small, red, solid elevations; surface of reaction has granular feeling
- **PU** Pustules – small, circumscribed, elevated and inflamed skin lesions, with pus at its centre.
- **V** Vesicles – small, circumscribed elevations having translucent surfaces so that fluid is visible (blister – like). Vesicles are no larger than 0.5 cm in diameter.
- **B** Bullae – vesicles with a diameter> 0.5 cm; vesicles may coalesce to form one or a few large blisters that fill the patch site.

Other responses could be observed:

- **S** Spreading – evidence of the reaction beyond the patch area
- **W** Weeping – evidence of release of fluid from a vesicular or bullous reaction
- **A** Marked reaction to adhesive (patch relocated).
- **X** Succeeding patch not applied and succeeding grade is for residual reaction

### 4.4. Interpretation of Results

The interpretation of the results of an HRIPT was carried out on a case-by-case basis using immunological principles, general interpretation guidelines and experience. The standard scoring scale used to interpret skin responses was provided in Table 1 and Table 2.

The following guidelines have been developed for the interpretation of reactions that may occur during an HRIPT.

- Skin sensitization reactions are most frequently erythematous, papular and edematous. Conversely, primary irritation reactions (unless severe), are generally erythematous only. An irritation reaction is usually uniform with a well-defined border, whereas an allergic response (especially if weak) is typically non-uniform and has an irregular border, and a strong response may spread beyond the patch site.
- Responses which are more severe at challenge than in early induction are suggestive of induction of skin sensitization.
- Responses confined to induction site during challenge phase are suggestive of irritation. True allergic reactions in challenge phase will occur at both site (induction site and virgin site) and persist through 2 delayed scorings at least 24 hours apart. However, unilateral allergic reactions can sometimes be observed. For this reason, all reactions considered suggestive of induction of skin sensitization should be followed up, for example, by re-challenge.
- Responses that increase or maintain severity with time from the 48 to 96 hours challenge gradings are presumptive of skin sensitization. Those that subside from the 48 to 96 hours grading period are generally considered to be irritant in nature.
- Edematous reactions that occur and persist during the latter part of the induction phase and the challenge phase are indicative of induced skin sensitization and should be confirmed by re-challenge.

- Persistent skin responses with papules and/or edema occurring in week 1 of induction suggest pre-existing skin sensitization. Similar reactions that occur later in induction suggest induction of skin sensitization by the test material.
- Reactions and reaction patterns that are suggestive of allergic reactions or questionable/equivocal reactions should be verified through appropriate re-challenge procedures.
- The reactions of any panelist(s) in question should always be compared with those of all other exposed panelists. Except in rare instances, allergic reactivity occurs in only a very small number of subjects, while irritation occurs more widely throughout the exposed population.

The HRIPT objective was to verify the absence of allergenic potential and the skin sensitization of a cosmetic product according to results from Induction phase and Challenge Phase. In parallel, a conclusion of the induction phase related to the cutaneous compatibility, could be drawn according to the calculation of the Mean Irritation Index (M.I.I.) global which was obtained according to average of the calculation of the daily Mean Irritation Index:

$$\textbf{Daily M. I. I.} = \frac{\sum(\bar{\textbf{x}}\ \textbf{of the erythema and oedema grade})}{\textbf{Number of panelists}}$$

The obtained index is used to classify the studied cosmetic product according to the following scale:

| M.I.I. | Product Classification |
|---|---|
| M.I.I.=0.000 | Non-Irritating (NI)/Very Good Cutaneous Compatibility |
| M.I.I. <0.022 | Non-Irritating (NI) / Good Cutaneous Compatibility |
| 0.022≤ M.I.I. <0.055 | Slightly Irritating (SI) / Intermediate Cutaneous Compatibility |
| 0.055≤ M.I.I. <0.111 | Moderately Irritating (NI) / Bad Cutaneous Compatibility |
| M.I.I. ≥0.111 | Irritating (I) / Very Bad Cutaneous Compatibility |

Table 2. Cutaneous compatibility cosmetic product classification index

## 5. RESULTS

The individual reading results are presented in Annex II.

Next table showed the Global M.I.I. after induction phase.

| M.I.I. | Results | No. reactive panelists | % reactive panelists |
|---|---|---|---|
| 0,033 | Slightly Irritating (SI)/Intermediate Cutaneous Compatibility | 18 | 31% |

Next table shows the results of Challenge or Memory phase:

| Challenge (Memory phase) | No. reactive panelists | | % reactive panelists | |
|---|---|---|---|---|
| | Induction area | Virgin area | Induction area | Virgin area |
| | 0 | 0 | 0% | 0 |

The individual reading results are presented in Annex III.

**Allergenicity result:**

The allergenicity result was set up from the results obtained in the induction phase and in the memory phase (induction area and virgin area).

| Results | No. panelists showing some kind of allergic reaction | % reactive panelists |
|---|---|---|
| | 0 | 0% |

## 6. SAMPLES AND DOCUMENTS TO BE STORED

The following documentation relating to the study will be stored in the facilities of Zurko Research following the provisions of ISO 9001:2015:

- Informed Consent Forms signed
- Study protocol and its modifications (signed)
- Primary data
- Final report and its modifications (signed)
- Documents provided by the sponsor

The documents will be stored during 5 years. After 5 years the sponsor will be asked about the possibility of extension because of the commercialization of the tested element.

A sample of the evaluated product (sufficient quantity for the execution of the study) will be stored in the Zurko Research samples library for 1 year from the start date of the study.

## 7. BIBLIOGRAPHICAL REFERENCES

1. SCCS (Scientific Committee on Consumer Safety), SCCS Notes of Guidance for the Testing of Cosmetic Ingredients and their Safety Evaluation 10th revision, 24-25 October 2018, SCCS/1602/18.

2. Patel, S.M., E. Patrick, and H.I. Maibach, 1976 "Animal, Human, and In Vitro Test Methods for Predicting Skin Irritation". Dermatotoxicology, Chpt. 33; 5th Ed., F.N. Marzulli; H.I. Maibach; Taylor and Frances.

3. Pauline M. McNamee, Anne Marie Api, David A. Basketter, G. Frank Gerberick, Deborah A. Gilpin, Barbar M. Hall, Ian Jowsey, Michael K. Robinson. A review of critical factors in the conduct and interpretation of the human repeat insult patch test. Regulatory Toxicology and Pharmacology 52 (2008) 24-34.

4. Valerie T. Politano, Anne Marie Api. The Research Institute for Fragance Materials´human repeated insult patch test protocol. Regulatory Toxicology and Pharmacology 52 (2008) 35-38.

5. Nueva Clasificación de tipos piel y sus implicaciones en Dermatología Cosmética. Revisión Dermatología Venezolana. Vol. 43, Nº 4, 2005. Leslie Baumann, Sadegh Amini, Eduardo Weiss.

## SIGNATURES

The undersigned declare that this study has been carried out in the essence of the Clinical Good Practices (Guideline for good clinical practice E6 (R2) of June 14th 2017, EMA/CHMP/ICH/135/1995 of May 1st 1996, European Parliament and Council Guideline 2001/20/CE – May 1st 2001).

The results here presented reflect accurately and completely the raw data of the study.

**Researcher:** I, the undersigned, Jesús González Cuartero, declare that this study has been **carried out** under my responsibility.

Jesús González Cuartero

**Dermatology Team**: Zurko's dermatology team, led by the dermatologist Javier Pedraz (medical license number: 283706434), and Natalia Zawierta, as adjunct dermatologist, declare that this study has been **reviewed** under their responsibility. In representation,

ZAWIERTA NATALIA MARIA - Y3942816D

**Annex I: Information relating to panelists**

| Panelists | | Age | Sex | Skin type | Photo-type |
|---|---|---|---|---|---|
| Ref. | Acronym | | | | |
| 1 | V01 | 59 | F | S | III |
| 2 | V02 | 51 | F | S | IV |
| 3 | V03 | 21 | F | S | II |
| 4 | V04 | 65 | F | S | IV |
| 5 | V05 | 29 | M | S | II |
| 6 | V06 | 51 | F | S | II |
| 7 | V07 | 51 | F | S | II |
| 8 | V09 | 31 | F | S | II |
| 9 | V11 | 58 | M | S | IV |
| 10 | V13 | 40 | F | S | III |
| 11 | V14 | 33 | F | S | II |
| 12 | V15 | 51 | F | S | II |
| 13 | V16 | 30 | F | S | IV |
| 14 | V17 | 23 | M | S | II |
| 15 | V18 | 18 | F | S | III |
| 16 | V19 | 45 | F | S | IV |
| 17 | V21 | 36 | M | S | III |
| 18 | V22 | 28 | F | S | III |
| 19 | V23 | 21 | F | S | III |
| 20 | V24 | 44 | F | S | IV |
| 21 | V26 | 31 | M | S | II |
| 22 | V27 | 66 | M | S | III |
| 23 | V28 | 39 | F | S | III |
| 24 | V30 | 51 | F | S | II |
| 25 | V32 | 52 | F | S | IV |
| 26 | V33 | 26 | F | S | IV |

| | | | | | |
|---|---|---|---|---|---|
| **27** | V34 | 48 | M | S | III |
| **28** | V35 | 50 | M | S | III |
| **29** | V36 | 42 | F | S | IV |
| **30** | V37 | 68 | F | S | II |
| **31** | V38 | 54 | F | S | II |
| **32** | V39 | 63 | F | S | III |
| **33** | V40 | 41 | F | S | II |
| **34** | V41 | 62 | F | S | III |
| **35** | V42 | 63 | F | S | III |
| **36** | V43 | 43 | F | S | III |
| **37** | V44 | 35 | F | S | III |
| **38** | V45 | 55 | M | S | III |
| **39** | V46 | 51 | F | S | III |
| **40** | V47 | 25 | F | S | III |
| **41** | V48 | 36 | F | S | III |
| **42** | V49 | 54 | F | S | III |
| **43** | V50 | 22 | F | S | III |
| **44** | V53 | 56 | F | S | III |
| **45** | V54 | 31 | F | S | III |
| **46** | V55 | 36 | F | S | IV |
| **47** | V56 | 26 | F | S | III |
| **48** | V57 | 40 | F | S | IV |
| **49** | V58 | 22 | F | S | III |
| **50** | V59 | 50 | F | S | II |
| **51** | V60 | 55 | F | S | III |
| **52** | V61 | 45 | F | S | III |

**M: male, F: female; R: non-sensitive, S: sensitive**

Two panelists (V08, V51) left the study due to reasons unrelated to it. Seven exclusions (V10, V12, V20, V25, V29, V31, V52) were decided for the researcher due to exaggerated reaction to the product.

**Annex II: Individual results from Induction phase**

| Panelists | | Reaction in Induction Phase (according to Table 1) | | | | | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | DAY 3 | | | DAY 5 | | | DAY 8 | | | DAY 10 | | | DAY 12 | | | DAY 15 | | | DAY 17 | | | DAY 19 | | | DAY 22 | | |
| Ref | Acr. | E | OE | Ot | E | OE | Ot | E | OE | Ot | E | OE | Ot | E | OE | Ot | E | OE | Ot | E | OE | Ot | E | OE | Ot | E | OE | Ot |
| 1 | V01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2 | V02 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 3 | V03 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 4 | V04 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| 5 | V05 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| 6 | V06 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 7 | V07 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 8 | V09 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 9 | V10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | / | / | / | / | / | / | / | / | / |
| 10 | V11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| 11 | V12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | / | / | / | / | / | / | / | / | / |
| 12 | V13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 13 | V14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 14 | V15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 15 | V16 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 16 | V17 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

| Panelists | | Reaction in Induction Phase (according to Table 1) | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | DAY 3 | | | DAY 5 | | | DAY 8 | | | DAY 10 | | | DAY 12 | | | DAY 15 | | | DAY 17 | | | DAY 19 | | | DAY 22 | | |
| Ref | Acr. | E | OE | Ot | E | OE | Ot | E | OE | Ot | E | OE | Ot | E | OE | Ot | E | OE | Ot | E | OE | Ot | E | OE | Ot | E | OE | Ot |
| 17 | V18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 18 | V19 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 19 | V20 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 |
| 20 | V21 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 21 | V22 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 22 | V23 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 23 | V24 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 24 | V25 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / |
| 25 | V26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 26 | V27 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 27 | V28 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 28 | V29 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 0 | / | / | / | / | / | / |
| 29 | V30 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 30 | V31 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | / | / | / | / | / | / | / | / | / |
| 31 | V32 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 32 | V33 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 33 | V34 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

| Panelists | | Reaction in Induction Phase (according to Table 1) | | | | | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | DAY 3 | | | DAY 5 | | | DAY 8 | | | DAY 10 | | | DAY 12 | | | DAY 15 | | | DAY 17 | | | DAY 19 | | | DAY 22 | | |
| Ref | Acr. | E | OE | Ot | E | OE | Ot | E | OE | Ot | E | OE | Ot | E | OE | Ot | E | OE | Ot | E | OE | Ot | E | OE | Ot | E | OE | Ot |
| 34 | V35 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 35 | V36 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 36 | V37 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| 37 | V38 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 38 | V39 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 39 | V40 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 40 | V41 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| 41 | V42 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 42 | V43 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 43 | V44 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 44 | V45 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 45 | V46 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 46 | V47 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 47 | V48 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| 48 | V49 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 49 | V50 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| 50 | V52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | / | / | / | / | / | / | / | / | / | / | / | / | / | / | / |

| Panelists | | Reaction in Induction Phase (according to Table 1) | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | DAY 3 | | | DAY 5 | | | DAY 8 | | | DAY 10 | | | DAY 12 | | | DAY 15 | | | DAY 17 | | | DAY 19 | | | DAY 22 | | |
| **Ref** | Acr. | E | OE | Ot | E | OE | Ot | E | OE | Ot | E | OE | Ot | E | OE | Ot | E | OE | Ot | E | OE | Ot | E | OE | Ot | E | OE | Ot |
| **51** | V53 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| **52** | V54 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| **53** | V55 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| **54** | V56 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| **55** | V57 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| **56** | V58 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| **57** | V59 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| **58** | V60 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| **59** | V61 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| **Daily M.I.I.** | | **0,008** | | | **0,000** | | | **0,017** | | | **0,026** | | | **0,018** | | | **0,088** | | | **0,065** | | | **0,047** | | | **0,047** | | |
| **Global M.I.I.** | | **0,033** | | | | | | | | | | | | | | | | | | | | | | | | | | |

**0: non-visible erythema, 1: slight erythema, 2: moderate erythema, 3: intense erythema**

**P: papules, PU: pustules, V: vesicles, B: bullae, S: spreading, W: weeping, X: residual pigmentation**

**Annex III: Individual Results from Challenge phase**

| Panelists | | Reaction in Challenge Memory phase | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | Induction Area | | | | Virgin Area | | | | Allergeniciy Result (-/+) |
| Ref. | Acronym | D36 | D38 | D39 | D40 | D36 | D38 | D39 | D40 | |
| 1 | V01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| 2 | V02 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| 3 | V03 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| 4 | V04 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| 5 | V05 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| 6 | V06 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| 7 | V07 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| 8 | V09 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| 9 | V11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| 10 | V13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| 11 | V14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| 12 | V15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| 13 | V16 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| 14 | V17 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| 15 | V18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| 16 | V19 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| 17 | V21 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| 18 | V22 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| 19 | V23 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| 20 | V24 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| 21 | V26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| 22 | V27 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| 23 | V28 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| 24 | V30 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| 25 | V32 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| 26 | V33 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| 27 | V34 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| 28 | V35 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| 29 | V36 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |

| Panelists | | Reaction in Challenge Memory phase | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | Induction Area | | | | Virgin Area | | | | Allergeniciy Result (-/+) |
| **Ref.** | Acronym | D36 | D38 | D39 | D40 | D36 | D38 | D39 | D40 | |
| **30** | V37 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| **31** | V38 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| **32** | V39 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| **33** | V40 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| **34** | V41 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| **35** | V42 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| **36** | V43 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| **37** | V44 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| **38** | V45 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| **39** | V46 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| **40** | V47 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| **41** | V48 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| **42** | V49 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| **43** | V50 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| **44** | V53 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| **45** | V54 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| **46** | V55 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| **47** | V56 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| **48** | V57 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| **49** | V58 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| **50** | V59 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| **51** | V60 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| **52** | V61 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |

**0: non-visible erythema, 1: slight erythema, 2: moderate erythema, 3: intense erythema**

eurofins | Pharma Control

Microbiologie
16, rue Clément Ader
F-68127 Sainte-Croix-en-Plaine
Tél 33 (0)3 89 22 27 74
Fax 33 (0)3 89 22 27 75
MicroPharmaControl@eurofins.com

# ACTIVITE BACTERICIDE

## RAPPORT D'ANALYSE

***Demandeur d'essais :*** Eurofins|ATS
Pôle d'activité Aix-Les-Milles
Actimart - 1140, rue Ampère
13851 Aix en Provence cedex 3

### 1 - Identification de l'échantillon :

| | |
|---|---|
| NOM DU PRODUIT : | **LINGETTES WC DESINFECTANTES REF 911057 AOUT 2013** |
| N° DE LOT : | **NA** |
| N° de l'échantillon (Eurofins) : | **31905-88606** |
| N° ATS : | **435301** |
| Date de réception : | 03/09/13 |
| Conditions de stockage : | Température ambiante |
| Aspect du produit : | Liquide limpide |

### 2- Mode opératoire :

NF EN 1276, Mars 2010

### 3- Méthode d'essai et sa validation :

| | |
|---|---|
| Méthode : | Filtration |
| Neutralisant : | Diluant neutralisant Pharmacopée (DNP) |

### 4- Conditions expérimentales :

| | |
|---|---|
| Date des essais : | 13/09/13 |
| Concentrations du produit : | 100% - 80% - 0,1% |
| Aspect des dilutions du produit : | Limpide |
| Temps de contact : | 5 minutes |
| Température d'essai : | Température ambiante (environ 20°C) |
| Stabilité du mélange : | Absence de précipité |
| Substance interférente : | 3g/ l albumine bovine en condition de saleté |
| Température d'incubation : | 36 ±1°C |

| Souches utilisées : | | |
|---|---|---|
| | *Staphylococcus aureus* | ATCC 6538 |
| | *Pseudomonas aeruginosa* | ATCC 15442 |
| | *Escherichia coli* | ATCC 10536 |
| | *Enterococcus hirae* | ATCC 10541 |

eurofins | Pharma Control

Microbiologie
16, rue Clément Ader
F-68127 Sainte-Croix-en-Plaine
Tél 33 (0)3 89 22 27 74
Fax 33 (0)3 89 22 27 75
MicrobioPharmaControl@eurofins.com

**5-1 : Vérification de la méthodologie et de la validation de la méthode par filtration pour le produit testé à 100% :**

| Germes | Temps en min | Nombre de cellules viables (UFC/ boites) | | | |
|---|---|---|---|---|---|
| | | Suspension de validation ($Nv_0$) | Témoin des conditions expérimentales (A) | Témoin de neutralisant (B) | Validation de la méthode(C) |
| *Staphylococcus aureus* ATCC 6538 | 5 | 52 | 73 | 44 | 47 |
| *Pseudomonas aeruginosa* ATCC 15442 | 5 | 70 | 78 | 70 | 58 |
| *Escherichia coli* ATCC 10536 | 5 | 60 | 58 | 63 | 52 |
| *Enterococcus hirae* ATCC 10541 | 5 | 50 | 68 | 53 | 48 |
| **Spécifications : $30 \leq Nv_0 \leq 160$ et A ; B ; $C \geq 0.5 \times Nv_0$** | | | | | |

La méthode est validée par filtration pour le produit testé 100%.

**5-2 : Résultats de l'essai :**

| Germes | Suspension bactérienne d'essai (N) (UFC/ml) ($N_0=Nx10^{-1}$) | Temps en min | Nombre de cellules viables (Na) pour les concentrations suivantes | | |
|---|---|---|---|---|---|
| | | | 100% | 80% | 0,1% |
| *Staphylococcus aureus* ATCC 6538 | $2,1.10^8$ | 5 | <140 | <140 | >1650 |
| *Pseudomonas aeruginosa* ATCC 15442 | $2,8.10^8$ | 5 | <140 | <140 | >1650 |
| *Escherichia coli* ATCC 10536 | $2,4.10^8$ | 5 | <140 | <140 | >1650 |
| *Enterococcus hirae* ATCC 10541 | $2,0.10^8$ | 5 | <140 | <140 | >1650 |
| | | | Taux de réduction : Log R= Log $N_0$- Log Na | | |
| | | | 100% | 80% | 0,1% |
| *Staphylococcus aureus* ATCC 6538 | | 5 | >5.2 | >5.2 | <4.1 |
| *Pseudomonas aeruginosa* ATCC 15442 | | 5 | >5.3 | >5.3 | <4.2 |
| *Escherichia coli* ATCC 10536 | | 5 | >5.2 | >5.2 | <4.2 |
| *Enterococcus hirae* ATCC 10541 | | 5 | >5.2 | >5.2 | <4.1 |

**Spécification** : Le produit est considéré comme conforme à la norme NF EN 1276 s'il est démontré, lors d'un essai valide, une réduction d'au moins 5 log en 5 min ou 1 min (pour la désinfection des mains) à 20 °C avec la substance interférente choisie simulant les conditions de propreté ou de saleté définies par la présente norme lorsque les microorganismes d'essai sont *Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus* et *Enterococcus hirae*. Les solutions d'essai du produit doivent être préparées à trois concentrations différentes au moins, de façon à inclure une concentration active et une concentration inactive.

**6 – Conclusion**

Le produit **« LINGETTES WC DESINFECTANTES REF 911057 AOUT 2013»** testé à 100%, 80% et 0,1% répond à la norme NF EN 1276 pour un temps de contact de 5 minutes en condition de saleté.

Technicien : EJ

Pharmacien

Angélique SABATIER

160913



SAS au capital de 110 800 € - RCS Nantes B 393 465 778 - Code APE : 731Z - TVA : FR 783 934 657 78 - www.eurofins-pharmacontrol.fr

# FDA approvals

## For the HWC series for the human body under the following regulations:

**FDA – VCRP 2511 No E1005747**

**FDA – VCRP 2512CPIS#: F1126426**

**Remarks:**

- The contents of this document must be 100% related accurately to the definitions as they appear in the original and complete records of the FDA under the regulatory numbers as listed above.

- Do not make changes or partially use the FDA definitions.

- Do not use FDA definitions or numbers without the prior written permission of

NANO Z COATING LTD.

- Under no circumstances shall NANO Z COATING LTD be responsible for any use of this document other than in accordance with the original use of the product as recorded in MSDS and in full compliance with FDA instructions.

**Nano Z coating LTD.** 1 Shedlovski St., Yavne, Israel **Tel.** +972-3-7166565
**E-mail.** nanot862@gmail.com **website.** www.nanoztec.com

U.S. Food and Drug Administration Center for Food Safety and Applied Nutrition
Office of Cosmetics and Colors

VCRP 2512 Menu » **Active CPIS List** **Active**

Label

Category

Brand Name

Ingredient

Filter Excel Download

**Record Count: 1**

| CPIS # | Brands | Labeler | Category | Filing Date |
|---|---|---|---|---|
| F1126426 | HWC-100 HYGIENIC WASHCLOTH<br>HWC-200 HYGIENIC WASHCLOTH FOR OUTDOOR SHOWER<br>HWC-300 EXTRA SOFT COSMETIC PAD | (84094) NANO Z COATING LTD | Other Personal Cleanliness Products | 07/21/17 |

U.S. Food and Drug Administration Center for Food Safety and Applied Nutrition
Office of Cosmetics and Colors

VCRP 2511 Menu » **Active Establishment List** **Active**

**Record Count: 1**

| Establishment # | Name | Parent Company | Date Filed |
|---|---|---|---|
| E1005747 | NANO Z COATING LTD | | 07/21/17 |